National Institutes of Health (NIH) Awards ResVita Bio a $2M Phase II SBIR Grant for Continuous Protein Therapy for Netherton Syndrome
ResVita Bio, a synthetic biology company, announces that the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) at the NIH has awarded the company a $2.03M Phase II Small ...
Adolore BioTherapeutics to Present at BioSparkVA Pitch Event
DELRAY BEACH, FL / ACCESSWIRE / September 24, 2024 / Adolore BioTherapeutics, Inc., ("Adolore" or the "Company"), a ...
Axena Health’s Leva System in Clinical Trial to Compare First-Line Treatments for Postpartum Urinary Incontinence
Leading medical centers will compare three first-line treatments for postpartum urinary incontinence NEWTON, Mass., September ...
Donald Trump Has a Plan to Make America's Children Healthy Again. It's a Good One | Opinion
The exorbitant cost of the failing health of our kids, the needless suffering and death, can be ended by a Kennedy Commission ...
Le Lézard1h
Enalare Receives FDA Clearance to Initiate the First Phase 1 Clinical Study of ENA-001 to Be Conducted in the United States
Enalare Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing novel compounds for the treatment of life-threatening critical care conditions and community health ...